Arovella Therapeutics Ltd (ALA) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.090x

Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) has a cash flow conversion efficiency ratio of -0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.71 Million ≈ $-1.21 Million USD) by net assets (AU$18.92 Million ≈ $13.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Arovella Therapeutics Ltd (ALA) balance sheet quality index to measure how much of total assets are equity-financed.

Arovella Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Arovella Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of Arovella Therapeutics Ltd to assess how comfortably operating cash covers total debt obligations.

Arovella Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Arovella Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Parkson Holdings Bhd KLSE:5657	0.129x
IRSA Propiedades Comerciales S.A BA:IRCP	0.019x
Sun Peak Metals Corp V:PEAK	-0.049x
Korea Parts & Fasteners Co.Ltd KQ:024880	0.085x
Optivision Technology TWO:3666	0.002x
TY Holdings Co Ltd KO:363280	-0.031x
Svolder AB (publ) ST:SVOL-A	0.002x
QTC Energy Public Company Limited BK:QTC	-0.052x

Annual Cash Flow Conversion Efficiency for Arovella Therapeutics Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Arovella Therapeutics Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Arovella Therapeutics Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$20.08 Million ≈ $14.21 Million	AU$-6.93 Million ≈ $-4.90 Million	-0.345x	+43.94%
2024-06-30	AU$11.23 Million ≈ $7.94 Million	AU$-6.91 Million ≈ $-4.89 Million	-0.616x	+63.62%
2023-06-30	AU$3.78 Million ≈ $2.67 Million	AU$-6.40 Million ≈ $-4.53 Million	-1.692x	-105.66%
2022-06-30	AU$7.62 Million ≈ $5.39 Million	AU$-6.27 Million ≈ $-4.44 Million	-0.823x	-108.53%
2021-06-30	AU$8.98 Million ≈ $6.36 Million	AU$-3.54 Million ≈ $-2.51 Million	-0.395x	+43.41%
2020-06-30	AU$4.14 Million ≈ $2.93 Million	AU$-2.88 Million ≈ $-2.04 Million	-0.697x	-290.58%
2019-06-30	AU$13.98 Million ≈ $9.89 Million	AU$-2.50 Million ≈ $-1.77 Million	-0.179x	+19.67%
2018-06-30	AU$11.46 Million ≈ $8.11 Million	AU$-2.55 Million ≈ $-1.80 Million	-0.222x	-338.46%
2017-06-30	AU$16.85 Million ≈ $11.92 Million	AU$-854.22K ≈ $-604.42K	-0.051x	+53.29%
2016-06-30	AU$16.61 Million ≈ $11.75 Million	AU$-1.80 Million ≈ $-1.28 Million	-0.109x	+33.60%
2015-06-30	AU$19.30 Million ≈ $13.66 Million	AU$-3.15 Million ≈ $-2.23 Million	-0.163x	+0.04%
2014-06-30	AU$15.99 Million ≈ $11.32 Million	AU$-2.61 Million ≈ $-1.85 Million	-0.164x	+32.03%
2013-06-30	AU$6.69 Million ≈ $4.73 Million	AU$-1.61 Million ≈ $-1.14 Million	-0.241x	--

About Arovella Therapeutics Ltd

AU:ALA Australia Biotechnology

Market Cap

$50.46 Million

AU$71.32 Million AUD

Market Cap Rank

#21870 Global

#767 in Australia

Share Price

AU$0.06

Change (1 day)

-1.67%

52-Week Range

AU$0.06 - AU$0.11

All Time High

AU$0.57